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Abstract: In Israel, Vipera xantina palestinae ( V.x.p.) is the most common venomous 
snake, accounting for several hundred cases of envenomation in humans and domestic 
animals every year, with a mortality rate of 0.5 to 2%. In this review we will briefly 
address the research developments relevant to our present understanding of the structure 
and function of V.x.p. venom with emphasis on venom disintegrins. Venom proteomics 
indicated the presence of four families of pharmacologically active compounds:   
(i) neurotoxins; (ii) hemorrhagins; (iii) angioneurin growth factors; and (iv) different types 
of integrin inhibitors. Viperistatin, a α1β1selective KTS disintegrin and VP12, a α2β1 
selective C-type lectin were discovered. These snake venom proteins represent promising 
tools for research and development of novel collagen receptor selective drugs. These 
discoveries are also relevant for future improvement of antivenom therapy towards V.x.p. 
envenomation. 
Keywords:  Vipera xantina palestinae; venom; neurotoxin; hemorrhagin; integrin 
inhibitors; antivenom 
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1. Introduction 
Snake bite is a serious medical problem, particularly in Asia, Africa and in the Middle East, 
including Israel. In Israel, Vipera xantina palestinae ( V.x.p.) is the most common venomous   
snake accounting for 100–300 reported cases of envenomation in adults, children and domestic 
animals every year [1] with a mortality rate of 0.5 to 2% [2,3]. The main symptoms following 
envenomation include hemorrhagic activity manifested in edema, alteration in the coagulation system, 
myotoxicity resulting in massive muscle fiber collagen desheeting and myonecrosis, cardiotoxicity  
and neurotoxicity often leading to strong hypotension, arrythmic pathologies, flaccid paralysis, 
disregulation of central autonomic vasoregulatory mechanism and respiratory paralysis [4]. The V.x.p. 
venom contains enzymes such as hyaluronidases, esterases, phosphodiesterases and L-amino acid 
oxidases [5] as well as neurotoxic phospholipase A2, and hemorrhagins. The above clinical local and 
systemic symptoms of V.x.p. envenomation are the consequence of the pharmacological activity of 
these enzymatic and non-enzymatic venom proteins. They cause increased capillary permeability, 
endothelial damage, platelet aggregation and dysfunction, thromboplastin and thrombin inhibition, 
neutrophilia, leucocytosis, thrombocytopenia, increase fibrinolysis and hypofibrinogenemia, release of 
histamines, kinins, and different presynaptic neurotoxic effects [6,7]. These pathological syndromes 
are induced by the large variety of proteins found in V.x.p. venom and by additive and synergistic 
interactions between them. 
In this review we will briefly address the research developments relevant to our present 
understanding on the structure and function of venom components of V.x.p. with emphasis on integrin 
inhibitors. These considerations are also relevant for future improvement of antivenom therapy 
towards V.x.p. envenomation. 
2. V.x.p. Venom Active Components  
2.1. Neurotoxins 
Isolation of neurotoxic and hemorragic factors from V.x.p. venom started in the 50s and 60s using 
chromatographic methods available at that time. Several toxic fractions were isolated and characterized 
from the venom of V.x.p. [8]. One of them was further isolated by Moroz-Perlmutter et al.,  
who demonstrated its lethality to mice and synergistically induced neurotoxicity with the venom 
protease fraction [9]. Later, Ovadia et al. [10] found that the neurotoxic fraction is composed of two 
proteins: an acidic protein (pI 4) endowed with phospholipase A2 (PLA2) (EC3.1.1.4) activity and a 
basic protein (pI 9.5) lacking any known enzymatic activity. Each of these proteins when injected into 
mice were not lethal but when injected together intravenously induced neurotoxicity with LD50 
between 50 and 100 µg/kg in mice [10]. These studies were continued by Bdolah and coworkers who 
demostrated that the acidic phospholipase is toxic and that substitution of this phospholipase with other 
phospholipases from different snakes can cause lethality in mice upon intavenous coinjection with the 
non-enzymatic basic component [11]. In the mid-90s, Krizaj et al. cloned the acidic PLA2 from V.x.p. 
(VpaPLA2) which has an apparent MW of 15 kDa, consisting of 122 amino acids and belonging to the 
subgroup IIA of PLA2s [12]. The neurotoxic mechanism of the two component system of the V.x.p. 
venom is not clear and the structure of the basic protein is yet unknown. Future studies are required to Toxins 2011, 3                                      
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characterize the interaction between VpaPLA2 and its basic counterpart including their unusual 
synergistic toxicity. 
2.2. Hemorrhagins 
In the early 60s, the group of De Vrise and Moroz isolated a hemorrhagic fraction from V.x.p. 
which is an acidic protein with an estimated MW of 44 kDa [13,14]. Later, Ovadia isolated three 
hemorrhagic factors from the V.x.p. venom, two of them with strong proteolytic activity on gelatin and 
casein as well as a capillary permeability-increasing albeit non-proteolytic activity, all of them in the 
range of 60 kDa MW [15]. In continuation to these studies Nakar and associates separated a proteolytic 
enzyme from one of the hemorrhagins. The two other hemorrhagins were endowed with proteolytic 
activity which could not be chromatographically separated from the hemorrhagic   
activity [16]. This strongly supported the concept that certain capillary permeability factor(s), devoid 
of proteolytic activity as well as several metalloproteases represent the hemorrhagins originally 
identified by Grotto et al. [14]. There has been a 25-year gap between these former chemical and 
pharmacological studies and nowadays, when more modern and advanced proteomic and 
pharmacological characterizations have approached to re-evaluate V.x.p. venom.  
2.3. Proteomics 
A preliminary proteomic analysis of V.x.p. venom is presented in Figure 1. The V.x.p. snakes, kept 
in a serpentarium in compliance with animal welfare regulation, were gently milked under good 
laboratory practice conditions (Figure 1A). The liquid venom was lyophilised and 200 mg dried venom 
was separated by C18 reverse phase HPLC into 17 fractions (Figure 1B). The fractions showing a 
single electrophoretic band (with or without additional separation by HPLC), were submitted for 
molecular mass, and N-terminal sequence determination, and mass spectrometry analysis as presented 
for VP12A (Figure 1C). The partial sequences of the proteins were assigned by BLAST analysis to 
known families of snake venom proteins. Although only few toxins from any particular reptile species 
are annotated in the databases, representative members of most toxin families of other snake species 
are available in the UniProtKB/Swiss-Prot v56.5 database [17] allowing the identification of the 
searched V.x.p. sequences. The analysis of V.x.p. venom HPLC fractions performed by MALDI-TOF 
indicated the presence of complex mixture of pharmacologically active molecules representing 
different percentage of whole venom according to the following distribution: (i) neurotoxins: 2% 
neurotoxic PLA2; 2% myotoxic PLA2; (ii) hemorrhagins: 65% zinc metalloproteinase, 9% different 
serine proteinases; (iii) angioneurin growth factors: about 2% of the venom is composed of snake 
homologues of vascular endothelial growth factor (VEGF) [18] and nerve growth factor (NGF) known 
to induce angiogenesis in blood capillaries, neurite outgrowth, as well as vascular permeability [19,20] 
and functionally also assigned to the hemorrhagin family; (iv) integrin inhibitors: 10% C-type   
lectin-related proteins (CLRPs), 6% dimeric disintegrin, 1% cystein rich disintegrin, <1% short 
disintegrins (hypothesized to represent additional hemorrhagins) [21]; (Figure 1D). This V.x.p. venom 
proteomics is in-line with snake venomics of other Vipera venoms, indicating a very similar 
composition [22]. It is evident that Vipera snakes produce a complex mixture of a large number of 
distinct proteins that pathologically modulate the cardiovascular and nervous system. In spite of the Toxins 2011, 3                                      
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fact that viperid venoms may contain over 100 protein compounds, these proteins can be sorted into 
enzymes (serine proteinases, zinc-metalloproteases,  L-amino acid oxidase, group II PLA2) and 
proteins without enzymatic activity, such as disintegrins, C-type lectin-related proteins (CLRPs), 
natriuretic peptides, myotoxins, cysteine-rich secretory protein (CRISP) toxins, nerve and vascular 
endothelium growth factors, cystatin, and Kunitz-type protease inhibitors  [22]. This situation may 
reﬂect the fact that these proteins evolved from a restricted set of gene protein families with normal, 
physiological functions that were modulated to serve a variety of novel pathologically offensive 
functions such as to induce neurotoxicity, hemorrhages, and muscle damage, thereby immobilizing and 
digesting the prey. This proteomic information requires further proof by biochemical and 
pharmacological studies of all HPLC isolated proteins both in vitro and in animal models. 
Figure 1. Scheme of the steps followed in the venomic investigation of Vipera xantina 
palestinae (V.x.p.). (A) Photograph of V.x.p. snake and manual milking of snake venom 
(Insert); (B) representative separation of venom components viperistatin and VP12 on C18 
reverse phase high-performance liquid chromatography (HPLC); (C) typical mass 
spectroscopy fragmentation spectra of isolated HPLC VP12A; (D) Scheme of the major 
groups of pharmacologically active protein in V.x.p. venom. 
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3.  V.x.p. Growth Factors: Vascular Endothelial Growth Factors (VEGF) and Nerve Growth 
Factor (NGF) 
Vascular endothelial growth factors (VEGF) are a family of proteins divided into seven subtypes: 
mammalian VEGF-A, B, C, D, placenta growth factor (PlGF), viral VEGF (VEGF-E), and snake 
venom VEGF (VEGF-F) [18]. The most characteristic structural feature of these VEGF ligands is the 
cysteine knot motif comprising three intertwined disulfide bridges. To date, only five receptors have 
been identified for the growing number of ligands [23]. Three belong to the receptor tyrosine kinase 
(RTK) family and are called fms-like tyrosine kinase-1 (Flt-1, also known as VEGFR-1) [24,25], 
kinase insert domain- containing receptor (KDR, VEGFR-2) [26,27], and Flt-4 (VEGFR-3) [28–30]. 
The others are non-tyrosine kinase-type receptors neuropilin-1 (NP-1) and neuropilin-2 (NP-2), which 
are believed to function as co-receptors for some VEGF subtypes and their isoforms [31,32]. Over ten 
different VEGF-F proteins have been identified. Snake venom VEGFs also show different degrees of 
selectivity in their interactions with different receptors and therefore have been divided into three 
groups [18]. VEGF-F1 is very selective for VEGFR-2, VEGF-F2 predominantly binds to VEGFR-1 
and weakly to VEGFR-2, and VEGF-F3 binds to both VEGFR-1 and VEGFR-2, as well as to NP-1. 
Snake venom VEGFs display potent endothelial cell proliferation, hypotensive activities, and vascular 
permeability induction when compared with VEGF-A165, the most physiologically abundant and 
investigated isoform of the VEGF-A family [33]. 
We have recently isolated and characterized VEGF-like angioneurin compounds from V.x.p. venom 
using two steps of reverse phase HPLC followed by protein sequencing yielding the following   
primary structure: 
ZVRPFLDVYQRSACQARETLVSILQEYPDEISDIFRPSCVAVLRCSGCCTDESLKC 
TPVGKHTVDMQIMRVNPRTQSSKMEVMKFTEHTACECRPRRKQGEPDGPKEKPR 
As expected, this growth factor [18] was able to induce in vivo plasma extravasation by causing 
microvessel leakage and in vitro increased permeability (reduction in electrical resistance) of brain 
capillary endothelial monolayer (Lecht, S.; Cohen, G.; Marcinkiewicz, C.; Lazarovici, P. 2008, 
unpublished data). These properties strongly suggest that this growth factor is another member of the 
hemorrhagin group of proteins in V.x.p. venom. The vipera VEGFs, like the natural human ligand 
VEGF-A165 exert their specific activity by binding to a VEGFR-2 but do not bind to the Flt or 
neuropilin receptor families [33]. For the first time unique pharmacological tools are available to study 
VEGF receptor type 2 function and for development of novel agonists and antagonists. 
Nerve growth factor (NGF) is a polypeptide which belongs to the neurotrophin family. The 
neurotrophin family includes four members: NGF, brain-derived neurotrophic factor (BDNF), 
neurotrophin3 (NT-3) and neurotrphin4/5 (NT-4/5) [34]. NGF plays the crucial role in the sympathetic 
and sensory nervous systems [35]. The biological functions of NGFs are mediated by two classes of 
cell surface receptors: the p75 neurotrophin receptor (p75
NTR), which recognizes all members of the 
neurotrophin family, and the tropomyosine kinase related receptor (trkA), belonging to the tyrosine 
kinase-neurotrophin receptor family [36]. Many NGFs have been isolated and characterized from all 
three families of snakes: Elapidae, Viperidae, Crotalidae [37–39]. We have initiated isolation and Toxins 2011, 3                                      
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purification of NGF from V.x.p. venom. This factor also induced weak vascular permeability 
suggesting its involvement in the hemorrhagic activity of V.x.p. venom (data not shown). 
Similar to snake venom VEGF-induced angiogenic effects, venom-derived NGFs promoted 
migration [40], capillary sprouting and other angiogenic functions [41] and may serve as unique 
pharmacological tools to study NGF actions. 
4. V.x.p. Integrin Inhibitors 
Disintegrins are the best known naturally occurring antagonists of integrins. Integrins are cell 
surface receptors, heterodimers of α and β subunits. Their main function is to shape and maintain the 
proper structure of tissue by mediating cell-cell and cell-extracellular matrix interactions. Besides their 
structural function, integrins have been identified as signaling molecules [42], resulting in cytoskeleton 
reorganization (shape change, adhesion, migration) [43–45], regulation of cell proliferation and cell 
survival and apoptosis [45–47]. 
Currently, classification of snake venom disintegrins can be performed based on their structure and 
function. The structural classification proposed by Marcinkiewicz presents two groups of disintegrins: 
monomeric and dimeric. Monomeric disintegrins can be divided into three subclasses regarding the 
number of cysteins in their structure: short, medium and long [48]. 
Functionally, disintegrins can be divided into three groups according to their integrin selectivity  
and presence of specific, recognition motifs. This classification includes RGD-disintegrins (binding  
to  αIIbβ3,  αvβ3,  α5β1 integrins which recognize fibrinogen, vitronectin and fibronectin),  
MLD-disintegrins (binding to α4β1, α4β7 integrins which binds to fibronectin, VCAM-1, MadCAM-1, 
and binding to α9β1 integrin which preferentially interacts with tenascin-C, osteopontin, VCAM-1, 
fibronectin, trombospondin-1, ADAM family members, and growth factors such as VEGF and NGF), 
and KTS-disintegrins (binding to the α1β1 integrin, a collagen receptor with particularly good affinity 
for collagen IV) [48,49]. 
Viperistatin, a KTS-disintegrin protein was isolated from V.x.p. venom by Kisiel et al. [21] using 
two-step reverse-phase high-performance liquid chromatography (HPLC) [50]. Viperistatin is a 
peptide of 4454.5 Da, containing eight cysteines residues engaged in the formation of four disulfide 
bonds. The complete primary structure of viperistatin determined by N-terminal sequencing showed 
high homology of this peptide to obtustatin, another KTS-containing disintegrin (Figure 2) [51], 
differing from it in just three residues at positons 24, 38 and 40. Viperistatin contains the same KTS 
motif in its active site as obtustatin and shows α1β1 integrin-blocking activity as well. However, it 
appeared to be a much more potent inhibitor of α1β1 integrin then obtustatin. In adhesion assay, 
viperistatin was 25 fold more active in inhibition of integrin α1 transfected K562 cell adhesion to both 
collagen IV and collagen I. The same trend was observed when inhibitory activity of viperistatin and 
obtustatin was compared in ELISA, where binding of purified α1β1 integrin to immobilized collagen 
type IV was investigated [21]. Structure-function analysis using synthetic, linear peptides that 
corresponded to the amino acid sequence of the entire integrin-binding loop for both obtustatin 
(CWKTSLTSHYC) and viperistatin (CWKTSRTSHYC), in adhesion and ELISA assay, indicated that 
replacement of a leucine (obtustatin) for an arginine (viperistatin) increased the inhibitory activity 
towards  α1β1 integrin by 6 to 10 fold [21] or even 25 fold [52] (Figure 2). The partial relative Toxins 2011, 3                                      
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enhancement of the inhibitory activity of the KTSR-peptide suggested that the L
38/V and P
40/Q 
substitution of viperistatin may also contribute to the biological activity of this disintegrin [21,52,53]. 
Figure 2. Comparison of the amino acid sequences of disintegrins: viperistatin (V.x.p. [21]) 
and obtustatin (V. lebetina obtusa [51]). Cysteines are in red and the active motifs are in 
italic. Amino acid residues that are different in obtustatin and viperistatin are in blue.  
1           5             10             15            20          25         30         35      40 
Obtustatin  CTTGPCCRQCKLKPAGTTCWKTS LTSHYCTGKSCDCPLYPG 
Viperistatin  CTTGPCCRQCKLKPAGTTCWKTSRTSHYCTGKSCDCPVYQG 
A C-type lectin-related protein (CLRP), called VP12 was also isolated from V.x.p. venom   
by Staniszewska et al., using two-step reverse-phase HPLC [54]. The amino acid sequence of   
VP12 subunits were established by a combination of mass spectrometry and N-terminal sequencing  
of their proteolytic fragments. While VP12A subunit sequence is completed, the VP12B subunit 
sequence is partial and needs to be completed and confirmed by DNA sequencing. MALDI-TOF MS 
analysis of unmodified VP12 yielded a single molecular ion of 30.387 Da, whereas VP12A and 
VP12B subunits showed 15.981 Da and 15.893 Da, respectively. Based on calculations and by 
comparison with the structure of another C-lectin type protein EMS-16 and rhodocetin [55,56] which 
have similar activity to VP12, it was predicted that each subunit of VP12 contains seven   
cysteines [54]. Although a large number of CLRP family proteins were reported, only few of them 
exhibit integrin binding properties [57]. In adhesion assay, VP12 showed a potent inhibitory effect on 
the adhesion of integrin α2β1 overexpressing K562 cells to collagen I (IC50 0.5 nM), but not on K562 
cells transfected with α1 integrin subunit to collagen IV. Also, the direct interaction of VP12 with 
α2β1 integrin was confirmed in adhesion assay. Cells transfected with the α2 integrin subunit showed a 
potent, dose-dependent adhesion to immobilized VP12, whereas non-transfected control cells did not 
interact with this CLRP [54]. This feature of VP12 was used for establishing of a technique for VP12 
isolation from V.x.p. venom, based on affinity chromatography targeting the A-domain of the   
α2β1 integrin [58]. 
By virtue of selective inhibiton of α1β1 or α2β1 integrins, respectively, viperistatin and VP12 are 
also active in blocking experimental metastasis of melanoma cell clones expressing these individual 
collagen receptors. This was shown in in vitro and in vivo experiments of inhibitory effects of both 
disintegrins on: adhesion of melanoma cells to collagen I and IV [58], transmigration of human 
melanoma cells through primary endothelial dermal human microvascular endothelial cells (dHMVEC) 
monolayers, as well as melanoma metastasis in a B16F10 mouse model [54,59]. Viperistatin and VP12 
demonstrated antimetastatic activity after injection into the tail vein of the mice at a dose lower than 
5 mg/kg, a concentration which is not toxic to the animals. 
All these studies provide KTS-peptides as lead compounds for the development of selective α1β1 
integrin antagonist drugs. Establishment of the full sequence of VP12 and elucidation of the binding 
motif of VP12 to α2β1 integrin would also offer the possibility to develop and synthesize cyclic 
peptides with α2β1 integrin-inhibiting potential. Such collagen receptor inhibitors would enable the 
design of a variety of drugs towards therapy of different cardiovascular diseases and cancer. Toxins 2011, 3                                      
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5. Antivenom Therapy of V.x.p. Envenomation 
Serotherapy is currently the main therapy for treating snake envenomation in general and V.x.p. in 
particular. In Israel, V.x.p. bites are among the most common reasons for human and veterinary 
envenomations and fatalities [7]. The Israeli Ministry of Health is producing V.x.p. antivenom in horse 
based on a protocol developed by Moroz et al. The antigen consisting of 40% venom, 30% neurotoxic 
fraction and 30% hemorrhagic fraction together with adjuvant generating an efficient antivenom 
therapy [6,60–62]. Dose regiment of 50 mL of V.x.p. antivenom was reported to be efficacious in the 
treatment of systemic and progressive local manifestation caused by this snake envenomation [6]. 
Common side effects associated with its use and mild neutralization of all local or systemic effects 
of the venom are calling for modern studies to evaluate the precise proteomic composition and 
pathophysiological activity as well as development of more effective therapeutic strategies to deal with 
snake venom envenomation [63]. The Global Snakebite Initiative (GSI) is the development of 
multinational collaborative project to develop new regional polyvalent antivenoms in Asia and Africa 
using phylogenetic, proteomic and antivenomic tools to optimize immunogen selection in order to 
ensure broad multi snake coverage [64]. Therefore, this new approach calls for re-evaluation of 
proteomics and venomics of V.x.p. We hope that in the near future the second generation of poyvalent 
anti-V.x.p.venom under development by Kamada Ltd., Kiryat Weizmann, Rehovot, Israel will be found 
more efficacious and safe, and compatible with GSI polyvalent antivenom strategy. 
6. Conclusions 
There is a need for the development of efficient V.x.p polyvalent antivenom to treat envenomated 
patients in Israel. The development of this antivenom requires a modern understanding of the 
proteomics and pharmacological functions of the individual venom components. Re-evaluation of 
V.x.p. venom composition and function has been pursued in our laboratories over the last decade. 
Angiogenic factors, vascular endothelial like growth factors and nerve growth factors have been 
isolated and characterized. Viperistatin, a α1β1selective KTS disintegrin and VP12, a α2β1 selective 
C-type lectin were discovered. These snake venom proteins, proposed to represent novel hemorrhagins 
are promising tools for future research and development of novel drugs selective for integrins. In 
addition, the fact that new targets of antivenom therapy appear by more recent proteomic description 
of  V.x.p. venom (such as the discovery of novel growth factors with hemorrhagic activities, of 
disintegrin and CLRPs), calls for re-evaluation of V.x.p. antivenom potential to neutralize these 
proteins. Full neutralization of all toxic components of V.x.p. venom is obligatory in order to achieve 
full protection of the patients. 
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